Lawsuit Filed Against Capricor Therapeutics for Securities Fraud

A securities fraud class action has been initiated against Capricor Therapeutics, Inc. (CAPR), with Levi & Korsinsky reminding investors of the deadline to join the lawsuit by September 15, 2025. The class action lawsuit alleges that Capricor made false and misleading statements to investors, which led to inflated stock prices. Investors who suffered losses as a result of this alleged securities fraud may be eligible to participate in the class action.

Capricor Therapeutics is facing accusations of providing misleading information that influenced investors’ decisions. Levi & Korsinsky is urging investors who suffered losses to join the class action lawsuit. The legal action revolves around allegations that Capricor made false statements regarding a key product, their CAP-1002 therapy, and its potential for FDA approval. These allegedly deceptive statements caused the company’s stock price to skyrocket, leading to losses for investors when the truth was revealed.

The class action lawsuit aims to hold Capricor Therapeutics accountable for the alleged securities fraud. Investors who purchased Capricor stock between January 14, 2022, and August 11, 2025, may be eligible to participate in the lawsuit. The deadline to join the class action is September 15, 2025.

The allegations against Capricor Therapeutics highlight the importance of transparency and honesty in the financial markets. Investors rely on accurate information to make informed decisions about their investments. When companies provide false or misleading statements, investors can suffer significant financial losses. Securities fraud class actions aim to protect investors by holding companies accountable for deceptive practices.

Investors who believe they have been affected by Capricor Therapeutics’ alleged securities fraud should consider joining the class action lawsuit. By participating in the legal action, investors may have the opportunity to recover their losses resulting from the misleading statements made by the company. Levi & Korsinsky is dedicated to helping investors seek justice in cases of securities fraud, ensuring that companies are held accountable for their actions.

The securities fraud class action against Capricor Therapeutics serves as a reminder of the risks that investors face in the financial markets. It is essential for investors to conduct thorough research and due diligence before making investment decisions. By staying informed and cautious, investors can protect themselves from potential fraud and deception in the market. Securities fraud class actions play a crucial role in holding companies accountable and seeking restitution for affected investors.